-+ 0.00%
-+ 0.00%
-+ 0.00%

Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026

PUBT·10/01/2026 20:06:07
Listen to the news
Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026
  • Mineralys Therapeutics announced new clinical and preclinical lorundrostat data will be presented at AHA Hypertension Scientific Sessions 2026 on Oct. 7-11.
  • A featured oral presentation will cover the Explore-OSA randomized crossover trial in obstructive sleep apnea with hypertension, focusing on efficacy and safety.
  • Additional presentations will highlight analyses from the Launch-HTN study in uncontrolled and resistant hypertension, including responder outcomes.
  • Preclinical findings slated for posters indicate lorundrostat reduced cardiorenal injury in a rat model, separate from blood pressure lowering.
  • Market-use research will review real-world spironolactone treatment patterns and adherence to mineralocorticoid receptor antagonists in resistant hypertension.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011605PRIMZONEFULLFEED9838220) on October 01, 2026, and is solely responsible for the information contained therein.